Vimarsana
Biggest News Aggregation in the World

Page 2 - Now Approved News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Now Approved. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Now Approved Today - Breaking & Trending Today

Merck & Co., Inc.: European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Vimarsana News

Merck & Co., Inc.: European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

KEYTRUDA Is Now Approved as Monotherapy for Adults With RCC at Increased Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions KEYTRUDA Is the First

FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection - Vimarsana News

FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC MelanomaKEYTRUDA Is Now Approved as Adjuvant Treatment for Patients (≥12 Years of Age) With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III DiseaseKENILWORTH, N.J.-...

European Commission Approves Merck's KEYTRUDA® Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer - Vimarsana News

European Commission Approves Merck's KEYTRUDA® Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer

KEYTRUDA Is Now Approved in Combination With Chemotherapy as First-Line Treatment for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 and Who Have Not Received Prior Chemotherapy for Metastatic Disease KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From ...

FDA Approves KEYTRUDA® Plus LENVIMA® Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma - Vimarsana News

FDA Approves KEYTRUDA® Plus LENVIMA® Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma

KEYTRUDA Plus LENVIMA Is Now Approved for Two Types of Cancer, Including Advanced RCC Based on Phase 3 CLEARKEYNOTE-581 Trial, KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib Merck known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration has approved the combination of KEYTRUDA, Merck’s anti-PD-1 ...

Facebook to Block Events Near U.S. Capitol: Inaugural Update - Vimarsana News

Facebook to Block Events Near U.S. Capitol: Inaugural Update

Facebook to Block Events Near U.S. Capitol: Inaugural Update Bloomberg 1/15/2021 Bloomberg News © Bloomberg The U.S. Capitol at sunrise in Washington, D.C., U.S., on Thursday, Jan. 14, 2021. President Trump's unprecedented second impeachment heads to the Senate, where his fate rests with Republican leader McConnell, who now has more leverage than ever over the president in his final week in office. (Bloomberg) -- Facebook Inc. said it will block users from creating events near the U.S. Capitol. Several key bridges to Washington will close on Tuesday, a day before the inau...

Source: msn.com